Skip to main content

Florence Mahoney Lecture on Aging

Sponsored by the National Institute on Aging, the series recognizes Mrs. Mahoney’s lifetime commitment to medical research and its benefits to people worldwide. Florence Stephenson Mahoney is widely known for her dedicated efforts in shaping national health science policy, particularly with respect to aging.

Charting the Path for Alzheimer’s Prevention: From Biomarkers to Therapeutic Targets

June 22, 2022 - 3:00pm to 4:00pm
Yakeel Quiroz, Ph.D., Harvard Medical School

Dr. Quiroz is Associate Professor in the Departments of Psychiatry and Neurology at Massachusetts General Hospital and Harvard Medical School, Boston, MA. She currently serves as Director of the MGH Familial Dementia Neuroimaging Lab, and Multicultural Alzheimer’s Prevention Program (MAPP). She completed her PhD in Clinical Psychology at Boston University and her Clinical Internship and Postdoctoral Fellowship in Neuropsychology at the MGH. Dr. Quiroz’s research interests focus on studying the neural underpinnings of memory dysfunction in the preclinical stages of Alzheimer’s disease (AD).

Understanding and Modeling Aging

April 7, 2021 - 3:00pm to 4:00pm
Anne Brunet, Ph.D., Stanford University

Dr. Brunet is interested in the molecular mechanisms of aging and longevity, with a particular emphasis on the nervous system. Her lab is interested in identifying pathways involved in delaying aging in response to external stimuli such as availability of nutrients and mates. She also seeks to understand the mechanisms that influence the rejuvenation of old stem cells. Finally, her lab has pioneered the naturally short-lived African killifish as a new model to explore the regulation of aging and age-related diseases.

Young Blood for Old Brains

March 31, 2021 - 3:00pm to 4:00pm
Tony Wyss-Coray, Ph.D., Stanford University

Dr. Wyss-Coray's laboratory studies the role of immune and injury responses in neurodegeneration and Alzheimer’s disease. We seek to understand how immune responses and injury pathways may modulate neurodegeneration and age-related changes in the brain. We study these pathways in vivo and in cell culture using a number of genetic and proteomic tools. We have been particularly interested in the TGF-beta signaling pathway as a major regulator of biological processes and we are developing genetic and pharmacological agents to manipulate this pathway.

Senescence: live fast, die young, and leave a good-looking corpse

November 28, 2018 - 3:00pm to 4:00pm
Norman E. Sharpless, M.D. , National Cancer Institute

In addition to serving as director of NCI, Dr. Sharpless continues his research in understanding the biology of the aging process that promotes the conversion of normal self-renewing cells into dysfunctional cancer cells. Dr. Sharpless has made seminal contributions to the understanding of the relationship between aging and cancer, and in the preclinical development of novel therapeutics for melanoma, lung cancer, and breast cancer.

From genetics to therapeutics in Alzheimer’s: accelerating translation, increasing success

May 9, 2018 - 3:00pm to 4:00pm
Lennart Mucke, M.D. , The J. David Gladstone Institutes

Dr. Mucke’s research focuses on conditions that cause cognitive deficits, behavioral abnormalities and other major neurological alterations, including aging-related dementias, epilepsy and neuropsychiatric disorders. He uses transgenic mouse models and neural cultures to dissect the pathogenic pathways that lead from genetic and environmental risk factors to neurological abnormalities at the molecular, cellular, network and behavioral level. Experimental models are also used to develop and evaluate novel treatment strategies.

Stem cells, aging, and aging stem cells

April 5, 2017 - 3:00pm to 4:00pm
Amy Wagers, Ph.D. , Harvard University

Research in Dr. Wagers’s lab seeks to discover fundamental principles that govern tissue aging and determine stem cell function in organ regeneration and degenerative disease. These efforts build upon novel discoveries and unique experimental models, which are defining the cellular and molecular networks that control muscle regenerative activity and uncovering common signals delivered via the bloodstream that can reverse the effects of aging across tissues.

Age, genes, sex, and smell: predicting Parkinson disease

May 4, 2016 - 3:00pm to 4:00pm
Andrew Singleton, Ph.D. , National Institute on Aging

Dr. Singleton's talk will focus on the most effective route to testing disease-modifying therapies in neurodegenerative disease earlier in the disease process, with a particular focus on Parkinson disease. He will discuss attempts to make headway in identifying at-risk patients as early as possible in the disease process, when interventions may be most effective.

A multiscale biology approach for dissecting the complex processes underlying aging and aging related phenotypes

October 1, 2014
Eric Schadt, Ph.D., Mount Sinai

The annual Mahoney Lecture is named in honor of Florence Stephenson Mahoney (1899–2002), who devoted the last half of her life to successfully advocating for the creation of the National Institute on Aging and increased support for NIH. During his lecture, Dr. Schadt will focus on the integration of the digital universe of information to better diagnose, treat, and prevent human disease. The lecture will feature the work of Dr.

Epigenetic regulation of senescence and aging

March 12, 2014
Shelley L. Berger, Ph.D., University of Pennsylvania Perelman School of Medicine

Aging is a crucial risk factor in a constellation of human diseases, including cancer and neurodegenerative diseases. Along with other risk factors such as environmental exposures, diet, behavior, and heredity, these risks can be understood through their impact on the epigenetic landscape in ways that ultimately lead to the burden of disease. Among these risks, aging had been regarded as fixed, but current thinking holds that aging is plastic and its pace can be slowed or even reversed. Dr.

The page was last updated on Thursday, January 29, 2015 - 2:31pm